Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
KAKairos Pharma, Ltd. logo

Kairos Pharma, Ltd. (KAPA)

New York Stock Exchange Arca · Currency in USD
$0.56 ▲ +0.01 (+2.67%)
At close: Oct 23, 3:59 PM ET. Market closed.
$0.54 ▼ -0.02 (-2.78%)
After hours: Oct 23, 6:11 PM ET

Summary

Previous Close
$0.54
Open
$0.54
Day's Range
$0.53 – $0.59
52 Week Range
$0.52 – $8.12
Volume
109,841
Avg. Volume
477,198
Market Cap
$1.89M
Beta (5Y Monthly)
1.44
PE Ratio (TTM)
--
EPS (TTM)
-$1.90
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Kairos Pharma, Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
4
CEO
John S. Yu

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.56
DateEst.Actual
Aug 12, 2026-$0.63-$0.42Beat
May 13, 2026-$0.07-$0.08Miss
Apr 21, 2026-$0.84-$0.07Beat
Nov 13, 2025-$0.70-$0.49Beat
Aug 13, 2025-$0.42-$0.08Beat
Apr 15, 2025-$0.05-$0.08Miss

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on KAPA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.